---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-002571"
form_type: "8-K"
ticker: null
cik: "0001642545"
company_name: "Shockwave Medical, Inc."
filed_at: "2024-05-06T23:59:59+00:00"
generated_at: "2026-06-02T22:09:39.590015+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Shockwave Medical Q1 revenue up 36% to $218.8M, net income $55.3M; withdraws 2024 guidance due to JNJ acquisition

## Summary
- Revenue $218.8M (+36% YoY); net income $55.3M ($1.44 diluted EPS) vs $39.1M ($1.01) in Q1 2023.
- Gross margin 87%; operating expenses $148.2M (+48% YoY) on sales force expansion.
- Adjusted EBITDA $68.5M, up 19% from $57.5M in Q1 2023.
- Withdraws full-year 2024 guidance due to proposed Johnson & Johnson acquisition.
- Cash, cash equivalents and short-term investments $1,029.2M as of March 31, 2024.

## SEC filing metadata
- accession: 0001171843-24-002571
- form_type: 8-K
- cik: 0001642545
- company_name: Shockwave Medical, Inc.
- filed_at: 2024-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642545/000117184324002571/0001171843-24-002571-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642545/000117184324002571/f8k_050624.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-002571
- JSON: https://secwatch.observer/filing/0001171843-24-002571.json
- Plain text: https://secwatch.observer/filing/0001171843-24-002571.txt

## Key facts
- Earnings Releases
  Shockwave Medical, Inc. reported first quarter ended March 31, 2024 results: revenue $218.8 million, net income $55.3 million, EPS $1.48 and $1.44.
  - Period: first quarter ended March 31, 2024
  - Revenue: $218.8 million
  - Net income: $55.3 million
  - EPS: $1.48 and $1.44
  - Result: reported results
  source text: to bring our life-changing therapies to even more patients across the globe.” First Quarter 2024 Financial Results Revenue for the first quarter ended March 31, 2024, was $218.8 million, a 36% increase from $161.1 million in the same period of 2023. The growth in revenue was primarily driven by increased adoption of Shockwave products in both the United States
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642545/000117184324002571/0001171843-24-002571-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.